PET-CT whole body scan detects underlying
cancer in patients with related neurologic complications
A combined positron emission tomography-computed tomography
(PET-CT) scan of the whole body appears to detect cancer in individuals with related
neurologic complications more accurately than some other commonly used tests,
according to a report posted online that will appear in the March print issue
of Archives of Neurology, one of the JAMA/Archives journals.
Paraneoplastic neurologic disorders occur in some people
with cancer-including lung, breast or ovarian cancer-and may develop when cancer-fighting
antibodies mistakenly attack cells in the nervous system. "In the assessment of
patients with suspected paraneoplastic neurologic disorders, routine non-invasive
oncologic evaluations may be unrevealing," the authors write as background information
in the article. "These standard evaluations include physical examination; computed
tomography (CT) of the chest, abdomen and pelvis; mammography in women; and testicular
ultrasonography and prostate-specific antigen testing in men." Cancers underlying
paraneoplastic neurologic disorders are typically small, restricted to one site
and are often not detected until autopsy.
Andrew McKeon, M.B., M.R.C.P.I., and colleagues at Mayo
Clinic, Rochester, MN, analyzed the medical records of 56 consecutive patients
with suspected paraneoplastic neurologic disorders whose standard evaluations
(including CT) did not reveal cancer. All of them underwent PET-CT at Mayo Clinic
between 2005 and 2008.
PET-CT detected abnormalities suggestive of cancer in
22 of the patients (39 percent), of whom 10 (18 percent) had cancer diagnoses
confirmed by biopsy or another method. Of these cancers, two were in the thyroid,
one was in the tonsil, three were in the lungs, one was in the colon and three
were cancerous lymph nodes with unknown primary cancer sites. Nine of the ten
were early-stage cancers, and detection facilitated early treatment. Cancer remission
was reported in seven patients and improvement in neurologic symptoms in five
patients after a median (midpoint) of 11 months of follow-up.
Before their PET-CT, patients underwent a median of three
other screening tests; the most common was CT of the chest, abdomen and pelvis.
"However, four of the 10 detected cancers using PET-CT were outside the anatomical
scope of CT of the chest, abdomen and pelvis (thyroid, two; cervical lymph node,
one; and palatine tonsil, one)," the authors write. "The other six detected cancers
were too small to be detected by appropriate regional CT (lung, four; axillary
lymph node, one; and colon, one). Clearly, CT alone is not sufficient to exclude
cancer in cases with a high index of suspicion for cancer."
Some types of cancer, including bladder and kidney cancers,
are more difficult to detect by PET-CT, the authors note. "Recognizing the limitations
of PET-CT, we favor this modality for initial oncologic evaluation of patients
in whom a paraneoplastic neurologic disorder is strongly suspected," they conclude.
"Elimination of whole-body imaging with CT alone before further imaging with PET-CT
could reduce radiation exposure and the total financial burden of testing."
|